Similarly to the mouse model, it was observed an increase of CD4+ T in patients that show cDC2 abundance to the detriment of Treg suggests that the combination of high levels of cDC2 and low levels of Treg correlate with better tumor prognosis and with clinical responsiveness to immunotherapy (including anti-PD-1 therapy), though the increase of the levels of CD4+ T cell infiltration (Quezada et al., 2006; Balachandran et al., 2011; Wallin et al., 2016). The gene discussed is CD4; the disease is neoplasm.